10x Genomics, Inc. (BMV:TXG)
Mexico
· Delayed Price · Currency is MXN 332.00
+30.00 (9.93%)
At close: Feb 13, 2026
10x Genomics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Revenue | 642.82 | 610.79 | 618.73 | 516.41 | 490.49 | Upgrade
|
| Revenue Growth (YoY) | 5.24% | -1.28% | 19.81% | 5.28% | 64.13% | Upgrade
|
| Cost of Revenue | 198.44 | 196.3 | 209.41 | 120.09 | 74.09 | Upgrade
|
| Gross Profit | 444.38 | 414.48 | 409.31 | 396.32 | 416.4 | Upgrade
|
| Selling, General & Admin | 310.13 | 343.24 | 343.33 | 295.8 | 257.56 | Upgrade
|
| Research & Development | 234.53 | 264.7 | 265.73 | 264.27 | 211.75 | Upgrade
|
| Operating Expenses | 544.67 | 607.94 | 609.06 | 560.07 | 469.31 | Upgrade
|
| Operating Income | -100.29 | -193.46 | -199.75 | -163.74 | -52.91 | Upgrade
|
| Interest Expense | - | -0 | -0.03 | -0.48 | -0.87 | Upgrade
|
| Interest & Investment Income | 20.05 | 18.93 | 16.89 | 6.65 | 0.21 | Upgrade
|
| Currency Exchange Gain (Loss) | 2.5 | -2.1 | 1.2 | 0.2 | -0.9 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.47 | 0.03 | -1.49 | -0.4 | 0.1 | Upgrade
|
| EBT Excluding Unusual Items | -79.21 | -176.6 | -183.18 | -157.77 | -54.38 | Upgrade
|
| Merger & Restructuring Charges | -10.6 | - | - | -4.2 | - | Upgrade
|
| Asset Writedown | - | -1.1 | -4.6 | - | - | Upgrade
|
| Legal Settlements | 49.9 | - | - | - | 0.66 | Upgrade
|
| Pretax Income | -39.91 | -177.7 | -248.76 | -161.97 | -53.72 | Upgrade
|
| Income Tax Expense | 3.64 | 4.93 | 6.34 | 4.03 | 4.51 | Upgrade
|
| Net Income | -43.54 | -182.63 | -255.1 | -166 | -58.22 | Upgrade
|
| Net Income to Common | -43.54 | -182.63 | -255.1 | -166 | -58.22 | Upgrade
|
| Shares Outstanding (Basic) | 125 | 120 | 117 | 114 | 110 | Upgrade
|
| Shares Outstanding (Diluted) | 125 | 120 | 117 | 114 | 110 | Upgrade
|
| Shares Change (YoY) | 3.57% | 2.80% | 2.90% | 3.18% | 9.09% | Upgrade
|
| EPS (Basic) | -0.35 | -1.52 | -2.18 | -1.46 | -0.53 | Upgrade
|
| EPS (Diluted) | -0.35 | -1.52 | -2.18 | -1.46 | -0.53 | Upgrade
|
| Free Cash Flow | 130.12 | -5.73 | -63.8 | -165.27 | -122.65 | Upgrade
|
| Free Cash Flow Per Share | 1.04 | -0.05 | -0.55 | -1.45 | -1.11 | Upgrade
|
| Gross Margin | 69.13% | 67.86% | 66.15% | 76.75% | 84.89% | Upgrade
|
| Operating Margin | -15.60% | -31.67% | -32.28% | -31.71% | -10.79% | Upgrade
|
| Profit Margin | -6.77% | -29.90% | -41.23% | -32.15% | -11.87% | Upgrade
|
| Free Cash Flow Margin | 20.24% | -0.94% | -10.31% | -32.00% | -25.01% | Upgrade
|
| EBITDA | -64.09 | -157.58 | -164.24 | -138.38 | -31.8 | Upgrade
|
| EBITDA Margin | -9.97% | -25.80% | -26.54% | -26.80% | -6.48% | Upgrade
|
| D&A For EBITDA | 36.2 | 35.88 | 35.51 | 25.37 | 21.12 | Upgrade
|
| EBIT | -100.29 | -193.46 | -199.75 | -163.74 | -52.91 | Upgrade
|
| EBIT Margin | -15.60% | -31.67% | -32.28% | -31.71% | -10.79% | Upgrade
|
| Revenue as Reported | 642.82 | 610.79 | 618.73 | - | - | Upgrade
|
| Advertising Expenses | 2.5 | 3.9 | 3.3 | 3.7 | 4.7 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.